BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hintzsche JD, Gorden NT, Amato CM, Kim J, Wuensch KE, Robinson SE, Applegate AJ, Couts KL, Medina TM, Wells KR, Wisell JA, McCarter MD, Box NF, Shellman YG, Gonzalez RC, Lewis KD, Tentler JJ, Tan AC, Robinson WA. Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma. Melanoma Res 2017;27:189-99. [PMID: 28296713 DOI: 10.1097/CMR.0000000000000345] [Cited by in Crossref: 68] [Cited by in F6Publishing: 37] [Article Influence: 17.0] [Reference Citation Analysis]
Number Citing Articles
1 Cai YJ, Ke LF, Zhang WW, Lu JP, Chen YP. Recurrent KRAS, KIT and SF3B1 mutations in melanoma of the female genital tract. BMC Cancer 2021;21:677. [PMID: 34102999 DOI: 10.1186/s12885-021-08427-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Eddy K, Chen S. Overcoming Immune Evasion in Melanoma. Int J Mol Sci 2020;21:E8984. [PMID: 33256089 DOI: 10.3390/ijms21238984] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
3 Buchbinder EI, Weirather JL, Manos M, Quattrochi BJ, Sholl LM, Brennick RC, Bowling P, Bailey N, Magarace L, Ott PA, Haq R, Izar B, Giobbie-Hurder A, Hodi FS. Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade. Cancer Med 2021;10:2627-35. [PMID: 33724703 DOI: 10.1002/cam4.3789] [Reference Citation Analysis]
4 Quek C, Rawson RV, Ferguson PM, Shang P, Silva I, Saw RPM, Shannon K, Thompson JF, Hayward NK, Long GV, Mann GJ, Scolyer RA, Wilmott JS. Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas. Oncotarget 2019;10:930-41. [PMID: 30847022 DOI: 10.18632/oncotarget.26584] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
5 Wong K, van der Weyden L, Schott CR, Foote A, Constantino-Casas F, Smith S, Dobson JM, Murchison EP, Wu H, Yeh I, Fullen DR, Joseph N, Bastian BC, Patel RM, Martincorena I, Robles-Espinoza CD, Iyer V, Kuijjer ML, Arends MJ, Brenn T, Harms PW, Wood GA, Adams DJ. Cross-species genomic landscape comparison of human mucosal melanoma with canine oral and equine melanoma. Nat Commun 2019;10:353. [PMID: 30664638 DOI: 10.1038/s41467-018-08081-1] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 15.0] [Reference Citation Analysis]
6 Khan S, Carvajal RD. Mucosal melanoma: current strategies and future directions. Expert Opinion on Orphan Drugs 2019;7:427-34. [DOI: 10.1080/21678707.2019.1672534] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
7 Yuan G, Song J, Li N, Song Q, Li Y, Du Y, Wang X, Jiao Y, Wu L. Telomere Maintenance Associated Mutations in the Genetic Landscape of Gynecological Mucosal Melanoma. Front Oncol. 2020;10:1707. [PMID: 32984050 DOI: 10.3389/fonc.2020.01707] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Hernandez-Prera JC. Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: The Neck and Lymph Nodes, Metastasis, and Melanocytic Tumors. Head Neck Pathol 2022. [PMID: 35312983 DOI: 10.1007/s12105-022-01433-w] [Reference Citation Analysis]
9 Obeng EA, Stewart C, Abdel-Wahab O. Altered RNA Processing in Cancer Pathogenesis and Therapy. Cancer Discov 2019;9:1493-510. [PMID: 31611195 DOI: 10.1158/2159-8290.CD-19-0399] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 13.0] [Reference Citation Analysis]
10 Sabbah M, Najem A, Krayem M, Awada A, Journe F, Ghanem GE. RTK Inhibitors in Melanoma: From Bench to Bedside. Cancers (Basel) 2021;13:1685. [PMID: 33918490 DOI: 10.3390/cancers13071685] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
11 Gkiala A, Palioura S. Conjunctival Melanoma: Update on Genetics, Epigenetics and Targeted Molecular and Immune-Based Therapies. Clin Ophthalmol 2020;14:3137-52. [PMID: 33116365 DOI: 10.2147/OPTH.S271569] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
12 Lasota J, Kowalik A, Felisiak-Golabek A, Zięba S, Waloszczyk P, Masiuk M, Wejman J, Szumilo J, Miettinen M. Primary malignant melanoma of esophagus: clinicopathologic characterization of 20 cases including molecular genetic profiling of 15 tumors. Mod Pathol 2019;32:957-66. [PMID: 30760858 DOI: 10.1038/s41379-018-0163-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
13 Eddy K, Chen S. Glutamatergic Signaling a Therapeutic Vulnerability in Melanoma. Cancers (Basel) 2021;13:3874. [PMID: 34359771 DOI: 10.3390/cancers13153874] [Reference Citation Analysis]
14 Newell F, Kong Y, Wilmott JS, Johansson PA, Ferguson PM, Cui C, Li Z, Kazakoff SH, Burke H, Dodds TJ, Patch AM, Nones K, Tembe V, Shang P, van der Weyden L, Wong K, Holmes O, Lo S, Leonard C, Wood S, Xu Q, Rawson RV, Mukhopadhyay P, Dummer R, Levesque MP, Jönsson G, Wang X, Yeh I, Wu H, Joseph N, Bastian BC, Long GV, Spillane AJ, Shannon KF, Thompson JF, Saw RPM, Adams DJ, Si L, Pearson JV, Hayward NK, Waddell N, Mann GJ, Guo J, Scolyer RA. Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nat Commun 2019;10:3163. [PMID: 31320640 DOI: 10.1038/s41467-019-11107-x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 72] [Article Influence: 26.3] [Reference Citation Analysis]
15 Dobrică EC, Vâjâitu C, Condrat CE, Crețoiu D, Popa I, Gaspar BS, Suciu N, Crețoiu SM, Varlas VN. Vulvar and Vaginal Melanomas-The Darker Shades of Gynecological Cancers. Biomedicines 2021;9:758. [PMID: 34209084 DOI: 10.3390/biomedicines9070758] [Reference Citation Analysis]
16 Krauthammer M. Unraveling the etiology of primary malignant melanoma of the esophagus. J Thorac Dis 2018;10:S1074-5. [PMID: 29850187 DOI: 10.21037/jtd.2018.03.91] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Vanni I, Tanda ET, Spagnolo F, Andreotti V, Bruno W, Ghiorzo P. The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape. Front Mol Biosci 2020;7:113. [PMID: 32695793 DOI: 10.3389/fmolb.2020.00113] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
18 Li J, Yan S, Wu N. Primary malignant melanoma of esophagus shared similar genetic characters with both cutaneous and oral mucosal melanoma. J Thorac Dis 2018;10:S2095-6. [PMID: 30023129 DOI: 10.21037/jtd.2018.05.158] [Reference Citation Analysis]
19 Rossi E, Schinzari G, Maiorano BA, Pagliara MM, Di Stefani A, Bria E, Peris K, Blasi MA, Tortora G. Conjunctival Melanoma: Genetic and Epigenetic Insights of a Distinct Type of Melanoma. Int J Mol Sci 2019;20:E5447. [PMID: 31683701 DOI: 10.3390/ijms20215447] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
20 Nassar KW, Tan AC. The mutational landscape of mucosal melanoma. Semin Cancer Biol 2020;61:139-48. [PMID: 31655118 DOI: 10.1016/j.semcancer.2019.09.013] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 7.7] [Reference Citation Analysis]
21 Nguyen JQN, Drabarek W, Yavuzyigitoglu S, Medico Salsench E, Verdijk RM, Naus NC, de Klein A, Kiliç E, Brosens E. Spliceosome Mutations in Uveal Melanoma. Int J Mol Sci 2020;21:E9546. [PMID: 33333932 DOI: 10.3390/ijms21249546] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
22 Gardrat S, Houy A, Brooks K, Cassoux N, Barnhill R, Dayot S, Bièche I, Raynal V, Baulande S, Marais R, Roman-Roman S, Stern MH, Rodrigues M. Definition of Biologically Distinct Groups of Conjunctival Melanomas According to Etiological Factors and Implications for Precision Medicine. Cancers (Basel) 2021;13:3836. [PMID: 34359736 DOI: 10.3390/cancers13153836] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Seiler M, Peng S, Agrawal AA, Palacino J, Teng T, Zhu P, Smith PG, Buonamici S, Yu L; Cancer Genome Atlas Research Network. Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. Cell Rep 2018;23:282-296.e4. [PMID: 29617667 DOI: 10.1016/j.celrep.2018.01.088] [Cited by in Crossref: 159] [Cited by in F6Publishing: 136] [Article Influence: 53.0] [Reference Citation Analysis]
24 Vanni I, Casula M, Pastorino L, Manca A, Dalmasso B, Andreotti V, Pisano M, Colombino M, Pfeffer U, Tanda ET, Rozzo C, Paliogiannis P, Cossu A, Ghiorzo P, Palmieri G; Italian Association for Cancer Research (AIRC) Study Group., Italian Melanoma Intergroup (IMI). Quality assessment of a clinical next-generation sequencing melanoma panel within the Italian Melanoma Intergroup (IMI). Diagn Pathol 2020;15:143. [PMID: 33317587 DOI: 10.1186/s13000-020-01052-5] [Reference Citation Analysis]
25 Ma Y, Xia R, Ma X, Judson-Torres RL, Zeng H. Mucosal Melanoma: Pathological Evolution, Pathway Dependency and Targeted Therapy. Front Oncol 2021;11:702287. [PMID: 34350118 DOI: 10.3389/fonc.2021.702287] [Reference Citation Analysis]
26 Li H, Yang L, Lai Y, Wang X, Han X, Liu S, Wang D, Li X, Hu N, Kong Y, Si L, Li Z. Genetic alteration of Chinese patients with rectal mucosal melanoma. BMC Cancer 2021;21:623. [PMID: 34044811 DOI: 10.1186/s12885-021-08383-6] [Reference Citation Analysis]
27 Carbó-bagué A, Rubió-casadevall J, Puigdemont M, Sanvisens A, Oliveras G, Coll M, del Olmo B, Perez-bueno F, Marcos-gragera R. Epidemiology and Molecular Profile of Mucosal Melanoma: A Population-Based Study in Southern Europe. Cancers 2022;14:780. [DOI: 10.3390/cancers14030780] [Reference Citation Analysis]
28 Rajkumar S, Berry D, Heney KA, Strong C, Ramsay L, Lajoie M, Alkallas R, Nguyen TT, Thomson C, Ahanfeshar-Adams M, Dankner M, Petrella T, Rose AAN, Siegel PM, Watson IR. Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy. Cell Rep 2022;39:110634. [PMID: 35385748 DOI: 10.1016/j.celrep.2022.110634] [Reference Citation Analysis]
29 Rose AM, Luo R, Radia UK, Kalirai H, Thornton S, Luthert PJ, Jayasena CN, Verity DH, Coupland SE, Rose GE. Detection of mutations in SF3B1, EIF1AX and GNAQ in primary orbital melanoma by candidate gene analysis. BMC Cancer 2018;18:1262. [PMID: 30558566 DOI: 10.1186/s12885-018-5190-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
30 Dumaz N, Jouenne F, Delyon J, Mourah S, Bensussan A, Lebbé C. Atypical BRAF and NRAS Mutations in Mucosal Melanoma. Cancers (Basel) 2019;11:E1133. [PMID: 31398831 DOI: 10.3390/cancers11081133] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
31 Han Y, Gu Z, Wu J, Huang X, Zhou R, Shi C, Tao W, Wang L, Wang Y, Zhou G, Li J, Zhang Z, Sun S. Repurposing Ponatinib as a Potent Agent against KIT Mutant Melanomas. Theranostics 2019;9:1952-64. [PMID: 31037149 DOI: 10.7150/thno.30890] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
32 Vivet-noguer R, Tarin M, Canbezdi C, Dayot S, Silva L, Houy A, Martineau S, Mieulet V, Gentric G, Loew D, Lombard B, Nemati F, Richon S, Guyonnet L, Servois V, Vagner S, Stern M, Roman-roman S, Alsafadi S. Glycolysis Dependency as a Hallmark of SF3B1-Mutated Cells. Cancers 2022;14:2113. [DOI: 10.3390/cancers14092113] [Reference Citation Analysis]
33 Prouteau A, André C. Canine Melanomas as Models for Human Melanomas: Clinical, Histological, and Genetic Comparison. Genes (Basel) 2019;10:E501. [PMID: 31262050 DOI: 10.3390/genes10070501] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 13.0] [Reference Citation Analysis]
34 Rabbie R, Ferguson P, Molina-Aguilar C, Adams DJ, Robles-Espinoza CD. Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities. J Pathol. 2019;247:539-551. [PMID: 30511391 DOI: 10.1002/path.5213] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 19.7] [Reference Citation Analysis]
35 Malaguarnera G, Madeddu R, Catania VE, Bertino G, Morelli L, Perrotta RE, Drago F, Malaguarnera M, Latteri S. Anorectal mucosal melanoma. Oncotarget 2018;9:8785-800. [PMID: 29492238 DOI: 10.18632/oncotarget.23835] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
36 Testa U, Castelli G, Pelosi E. Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells. Med Sci (Basel) 2017;5:E28. [PMID: 29156643 DOI: 10.3390/medsci5040028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
37 Amato CM, Hintzsche JD, Wells K, Applegate A, Gorden NT, Vorwald VM, Tobin RP, Nassar K, Shellman YG, Kim J, Medina TM, Rioth M, Lewis KD, McCarter MD, Gonzalez R, Tan AC, Robinson WA. Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy. Cancers (Basel) 2020;12:E1943. [PMID: 32708981 DOI: 10.3390/cancers12071943] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
38 van Poppelen NM, van Ipenburg JA, van den Bosch Q, Vaarwater J, Brands T, Eussen B, Magielsen F, Dubbink HJ, Paridaens D, Brosens E, Naus N, de Klein A, Kiliç E, Verdijk RM. Molecular Genetics of Conjunctival Melanoma and Prognostic Value of TERT Promoter Mutation Analysis. Int J Mol Sci 2021;22:5784. [PMID: 34071371 DOI: 10.3390/ijms22115784] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Chacón M, Pfluger Y, Angel M, Waisberg F, Enrico D. Uncommon Subtypes of Malignant Melanomas: A Review Based on Clinical and Molecular Perspectives. Cancers (Basel) 2020;12:E2362. [PMID: 32825562 DOI: 10.3390/cancers12092362] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
40 Wróblewska JP, Dias-Santagata D, Ustaszewski A, Wu CL, Fujimoto M, Selim MA, Biernat W, Ryś J, Marszalek A, Hoang MP. Prognostic Roles of BRAF, KIT, NRAS, IGF2R and SF3B1 Mutations in Mucosal Melanomas. Cells 2021;10:2216. [PMID: 34571863 DOI: 10.3390/cells10092216] [Reference Citation Analysis]
41 Mukherjee N, Amato CM, Skees J, Todd KJ, Lambert KA, Robinson WA, Van Gulick R, Weight RM, Dart CR, Tobin RP, McCarter MD, Fujita M, Norris DA, Shellman YG. Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma. Cancers (Basel) 2020;12:E2182. [PMID: 32764384 DOI: 10.3390/cancers12082182] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
42 Ottaviano M, Giunta EF, Marandino L, Tortora M, Attademo L, Bosso D, Cardalesi C, Fabbrocini A, Rosanova M, Silvestri A, Montella L, Tammaro P, Marra E, Trojaniello C, Vitale MG, Simeone E, Troiani T, Daniele B, Ascierto PA. Anorectal and Genital Mucosal Melanoma: Diagnostic Challenges, Current Knowledge and Therapeutic Opportunities of Rare Melanomas. Biomedicines 2022;10:150. [DOI: 10.3390/biomedicines10010150] [Reference Citation Analysis]
43 Gajan A, Martin CE, Kim S, Joshi M, Michelhaugh SK, Sloma I, Mittal S, Firestine S, Shekhar MPV. Alternative Splicing of RAD6B and Not RAD6A is Selectively Increased in Melanoma: Identification and Functional Characterization. Cells 2019;8:E1375. [PMID: 31683936 DOI: 10.3390/cells8111375] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]